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Munjal M. Acharya1*
Abstract
Numerous clinical studies have established the debilitating neurocognitive side effects of chemotherapy in the
treatment of breast cancer, often referred as chemobrain. We hypothesize that cognitive impairments are
associated with elevated microglial inflammation in the brain. Thus, either elimination of microglia or restoration of
microglial function could ameliorate cognitive dysfunction. Using a rodent model of chronic Adriamycin (ADR)
treatment, a commonly used breast cancer chemotherapy, we evaluated two strategies to ameliorate chemobrain:
1) microglia depletion using the colony stimulating factor-1 receptor (CSF1R) inhibitor PLX5622 and 2) human
induced pluripotent stem cell-derived microglia (iMG)-derived extracellular vesicle (EV) treatment. In strategy 1 mice
received ADR once weekly for 4 weeks and were then administered CSF1R inhibitor (PLX5622) starting 72 h post-
ADR treatment. ADR-treated animals given a normal diet exhibited significant behavioral deficits and increased
microglial activation 4–6 weeks later. PLX5622-treated mice exhibited no ADR-related cognitive deficits and near
complete depletion of IBA-1 and CD68+ microglia in the brain. Cytokine and RNA sequencing analysis for
inflammation pathways validated these findings. In strategy 2, 1 week after the last ADR treatment, mice received
retro-orbital vein injections of iMG-EV (once weekly for 4 weeks) and 1 week later, mice underwent behavior testing.
ADR-treated mice receiving EV showed nearly complete restoration of cognitive function and significant reductions
in microglial activation as compared to untreated ADR mice. Our data demonstrate that ADR treatment elevates
CNS inflammation that is linked to cognitive dysfunction and that attenuation of neuroinflammation reverses the
adverse neurocognitive effects of chemotherapy.
Keywords: Chemotherapy, Adriamycin, Doxorubicin, Chemobrain, Neuroinflammation, Cognitive dysfunction,
Colony stimulating factor receptor 1, Microglia, Extracellular vesicles, Induced pluripotent stem cells
Introduction
The clinical benefits of chemotherapy are achieved
through acute cytotoxicity, however this toxicity also
translates into chronic adverse neurocognitive outcomes,
often referred to as chemobrain [7]. This is particularly
prevalent in breast cancer survivors, the most common
form of invasive cancer in women. Currently, there are
over 3.1 million breast cancer survivors in the U.S. and
about 268,000 new cases will be diagnosed each year
[11]. Many of these breast cancer survivors (17 to 75%)
experience subtle to severe emotional, behavioral and
cognitive decrements that affect their ability to concen-
trate, plan, multitask and remember [42]. For these rea-
sons cognitive status is now, after survival, considered
the most important clinical criterion for evaluating
therapeutic outcome. The conspicuous absence of miti-
gation strategies for reducing the progressive neurocog-
nitive side effects represents a critical unmet medical
need and, breast cancer survivors represent a significant
patient base whose quality of life would be improved by
therapeutic interventions.
Pre-clinical chemobrain models have established the neu-
rocognitive and neurobiological consequences of com-
monly used chemotherapeutic agents for breast cancer
therapy [reviewed in [40]]. We have shown that chronic
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cyclophosphamide (CYP) or doxorubicin (Adriamycin,
ADR) monotherapy severely impairs hippocampal- and
frontal cortex-dependent cognitive function in rodents
[5, 22] that were linked with decline in neurogenesis,
mature neuron structure damage and persistent in-
flammation (i.e. microglial activation). Acute ADR ex-
posure was associated with reduced hippocampal
LTP, elevated lipid peroxidation and apoptosis [9].
Despite the very low penetrance of CYP or ADR
across the blood brain barrier (BBB), acute CYP or
ADR treatments negatively impacted hippocampal cell
proliferation and increased cell death demonstrating
the extreme sensitivity of the CNS to chemotherapy
[32, 51]. In rodents, combined ADR and CYP treat-
ment impaired contextual fear conditioning memory
and passive avoidance tasks and, elevated oxidative
stress and inflammation [13, 35]. These studies sug-
gest that exposure of the brain parenchyma to even
low levels of drug may be sufficient to disrupt sensi-
tive, rapidly dividing cells in neurogenic regions and
elevate neuroinflammation long after cessation of
chemotherapy. Pre-clinical and clinical reports also
suggest that treatment with ADR acutely elevates
plasma TNFα that may perturb the integrity of the
BBB and exacerbate inflammatory cascades in the
CNS leading to brain injury [48].
Pharmacological and non-pharmacological interventions
to alleviate chemobrain have shown only marginal benefits
[reviewed in [40]]. These include neuropsychological or
cognitive behavioral therapy, physical exercise and treat-
ment with drugs targeting neurotransmitter systems, al-
beit the pharmacological approach was also associated
with significant side effects. Based on our past studies
using rodent models of cancer therapy (e.g. irradiation
and/or chemotherapy)-related cognitive impairments we
hypothesize that persistent neuroinflammation is one of
the major drivers of brain injury and cognitive dysfunction
[3–6, 17]. Consequently, using a cranial radiation-induced
brain injury model, we showed that dietary treatment with
a colony stimulating factor-1 receptor (CSF1R) inhibitor
(PLX5622) [4], stem cells [3], or stem cell-derived extra-
cellular vesicle (EV) [17] transplantation ameliorated be-
havioral impairments in the irradiated animals. A number
of CSF1R inhibitors are currently under evaluation in the
clinic for cancer therapy [21]. Moreover, stem cell-derived
EVs protected from radiation-induced CNS inflammation
– a parallel neuropathology reported in chemobrain
models [17]. In this report, we now show the beneficial
neurocognitive and anti-inflammatory effects of two dis-
tinct strategies including a dietary treatment with the
CSF-1R inhibitor PLX5622 and intravenous injections of
EV isolated from human induced pluripotent stem cell
(iPSC)-derived microglia (iMG) in a mouse model of
ADR-induced cognitive impairments.
Materials and methods
Details on materials, experimental methods, behavior
and immunostaining protocols are provided in the Add-
itional file 1 section.
Animals and treatments
All animal procedures are approved by the Institutional
Animal Care and Use Committee and, according to the
federal (NIH) guidelines. Six-month old male wild type
mice (C57BL/6 J, Jackson) received ADR (doxorubicin
hydrochloride, Sigma) dissolved in saline (2mg/kg, once
weekly, i.p.) for 4 weeks as shown in the study design
(Fig. 1a). For the CSF1R inhibition study, mice were di-
vided into three experimental groups (N = 10–12 mice per
group): saline treated control mice receiving control chow
(Control), ADR-treated mice receiving control chow
(ADR) and, ADR-treated mice receiving PLX5622 chow
(ADR + PLX5622). 72 h after the last ADR injection mice
were provided the control or CSF1R inhibitor. PLX5622
chow, was provided by Plexxikon (Berkeley, CA) and for-
mulated in AIN-76A standard chow by Research Diets
(New Brunswick, NJ) at a dose of 1200 PPM. Control mice
received AIN-76A chow without PLX5622. The rationale
for using male mice is based on our past chemobrain stud-
ies using Adriamycin and cyclophosphamide showing the
detrimental neurocognitive and neurodegenerative effects
of these drugs on CNS function [22]. We conducted this
proof-of-concept countermeasure study using male mice
given our established chemobrain model and cognitive
testing protocols, and to avoid potential hormonal influ-
ences on cognitive function. All mice were maintained on
their respective PLX5622 or control diet throughout the
duration of the study.
EV were isolated from human iPSC-derived microglia.
Human microglia (iMG) were differentiated by a simpli-
fied method from human iPSC-derived mesodermal,
hematopoietic stem cells as described [1, 41]. RNA
sequencing, phagocytosis, and transplantation studies
validated the functional microglial characteristics of
these cells [1, 41]. Briefly, large batches of conditioned
medium were collected by Research and Development
Laboratory, Cellular Dynamics, Inc. (Madison, WI) dur-
ing the maturation phase (days 28 to 35) of the differen-
tiated iMG culture and refrigerated conditioned media
was shipped to UCI for the isolation of EV. EV isolation
was carried out using the ultracentrifugation protocol as
described in detail [17, 49]. EV quantity and size were
determined using ZetaView PMX110 particle analyzer
(Meerbusch, Germany). The iMG conditioned media
yielded a total of 7.07 × 1011 EV per ml with the mean
diameter of 65 nm. The purified EV were stored in ster-
ile phosphate buffered saline (PBS, 100 mM, pH 7.4,
Gibco) at 4 °C. Animals were divided into three groups
(N = 8 mice per group): Controls receiving PBS
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Fig. 1 Treatment with CSF1R inhibitor reverses Adriamycin-induced cognitive impairments. a, Schematic presentation of the study design: Six-
month old wild type (C57BL/6 J) male mice were injected with vehicle or Adriamycin (ADR, 2 mg/kg, i.p.), once weekly for 4 weeks. 72 h after the
last ADR injection, mice began treatment with the CSF1R inhibitor PLX5622 in rodent chow and continued on diet till the end of the study. ADR-
treated animals that received control chow served as vehicle group. One month after initiation of PLX5622 treatment, mice were administered
spatial and episodic memory retention testing using the novel object recognition (NOR) and object in place (OIP) tasks followed by fear
conditioning (FC) task. After completion of cognitive testing brains were collected for immunohistochemistry, RNA sequencing and cytokine
analyses. b, c The tendency to explore novel spatial locations or objects was derived from the Discrimination Index, calculated as ([Novel object
exploration time/Total exploration time] – [Familiar object exploration time/Total exploration time]) × 100. Chronic treatment with ADR
significantly impaired cognitive function. Preference towards the novel object (NOR task, *, P’s < 0.01 compared to ADR group, b, c) was
significantly reduced in the ADR-treated group receiving control diet. In contrast, ADR-treated mice receiving the PLX5622 diet showed significant
improvements on the performance on both NOR and OIP tasks (**, P’s < 0.006 compared to ADR group, b, c). d Treatment with CSF1R inhibitor
improves cognitive function on the hippocampal-dependent contextual fear-conditioning task. The baseline freezing levels were comparable
among groups, and all groups (Control, ADR and ADR + PLX5622) showed elevated freezing behavior following a series of 5 tone-shock pairings
(post-training). 24 h after fear conditioning training, the context test was administered where the ADR-treated mice receiving control diet showed
significantly decreased freezing compared to Controls (**, P < 0.006). ADR-treated mice receiving PLX5622 diet (ADR + PLX5622) showed a
significant elevation in freezing behavior compared to ADR treated mice receiving the control diet (*, P < 0 .01), and the level of freezing was
indistinguishable from the control group. After the initial training phase (48 h), the context (spatial environment) and the odor was changed that
resulted in a considerable reduction in freezing behavior (Pre-Cue bars) that was restored when tone was played (Post-Cue test bars), indicating
intact amygdala function in all groups. Data are presented as mean ± SEM (N = 10 mice per group). P values were derived from ANOVA and
Bonferroni’s post hoc test
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(Controls), ADR-treated receiving PBS (ADR) and ADR
receiving iMG-EV injection via retro-orbital sinus route
of administration once weekly for 4 weeks (1.36 × 107
EV per 50 μL per injection; ADR + iMG-EV). We did not
observe significant effects of any of these treatments on
animal body weights (Additional file 1: Figure S1).
Cognitive testing
To determine the effect of CSF1R inhibition on cognitive
function after chronic chemotherapy, mice were adminis-
tered behavioral testing 4 weeks after the initiation of
PLX5622 treatment. Testing spanned over 3 weeks includ-
ing the spontaneous exploration tasks Novel Object Recog-
nition (NOR) and Object in Place (OiP), followed by the
contextual and cued fear conditioning (FC) task. The NOR
task evaluates episodic recognition memory through meas-
uring the preference of mice to investigate novel object en-
vironmental changes, whereas the OiP task evaluates
associative recognition memory [15, 16]. The discrimin-
ation index was then calculated for each mouse from these
values: [(Novel/Total exploration time) – (Familiar/Total
exploration time)] × 100. A positive index indicates that an-
imals spent more time exploring novelty. A negative score
indicates that animals exhibited little or no preference for
novelty. After completion of spontaneous exploration tasks,
the FC task was administered in three sequential phases
over 3 days including a training phase, a context test and a
cue test as described previously [5, 22].
For the iMG-EV treatment study, cognitive function, in-
cluding NOR and fear extinction (FE) memory testing, were
carried out 1 week after the last EV injection (5 weeks after
the last ADR treatment). NOR testing was carried out as
described above. To determine if chronic chemotherapy or
EV treatment affects hippocampal-dependent fear condi-
tioning learning and memory consolidation, we performed
a series of FE assays modified to be reliant on hippocampal
function (see Additional file 1 for details). On first day of
conditioning, animals were presented with three pairing of
auditory stimulus co-terminating with a mild foot shock.
On the following 2 days (extinction training), animals were
presented with 20 tones in the same contextual environ-
ment (odor and cues). On the final day of fear testing, ani-
mals were presented with only three tones in the same
context. Freezing behavior was recorded using ceiling-
mounted camera in the test chamber and scored by an au-
tomated measurement program (FreezeFrame, Coulbourn
Instruments). The percentage of time each mouse spent
freezing during the tone was then calculated for each phase
of the fear response testing.
Immunohistochemistry, confocal microscopy and
volumetric quantification
After completion of behavioral testing, mice were deeply
anesthetized using isoflurane and euthanized via intercardiac
perfusion using saline with heparin (10U/ml, Sigma)
followed by 4% paraformaldehyde in PBS (ACROS Organics,
NJ). Coronal brain sections (30 μm thick, 3–4 sections per
brain) from each of 4–6 animals per experimental group
were selected for the immunofluorescence analysis of micro-
glia (IBA-1 and CD68) as described [3, 4]. Confocal z stacks
were collected for the quantification of IBA-1+ and CD68+
cells using 3D algorithm-based volumetric analyses (Auto-
QuantX3, MediaCybernetics and, Imaris, v9.2, Bit Plane Inc.,
Switzerland) as described [2, 4]. Data are expressed as mean
immunoreactivity (percentage) relative to the vehicle-treated
controls.
Cytokine and gene expression analyses
Freshly dissected hippocampi from each brain (N = 3–5
per group) were homogenized, washed and supernatants
were shipped to Quansys Biosciences (Logan, UT) for
the multiplex cytokines analysis using Q-Plex 14 cyto-
kine array kit. Positive readouts were reported and plot-
ted as the mean ± SEM. For the gene expression analysis,
total mRNA was extracted and, microglial function and
pro-inflammatory genes were analyzed using the Nano-
String mouse immunology panel (NanoString Technolo-
gies). Gene expression values were presented as percentage
of vehicle-treated control group.
Statistical analysis
Statistical analyses were carried out using GraphPad
Prism (v6). One-way ANOVA were used to assess
significance between the groups. When overall group ef-
fects were found to be statistically significant, a Bonfer-
roni’s multiple comparisons test was used to compare
the ADR with individual experimental groups. For ana-
lysis of fear conditioning and fear extinction data, re-
peated measures two-way ANOVA were performed.
Wilcoxon matched-pairs signed rank test was used to
compare exploration of same animals with familiar ver-
sus novel objects or places and, freezing behavior during
the day of extinction training versus test phases. All ana-
lyses considered a value of P ≤ 0.05 to be statistically
significant.
Results
CSF1R inhibition mitigates ADR treatment-induced
behavioral impairments
One month after initiation of PLX5622 treatment (Fig. 1a),
mice were habituated and tested on the NOR task (Fig. 1b).
For the test phase, a significant overall group difference was
found between the treatment cohorts for the discrimination
index (F(2, 27) = 7.04, P = 0.004). After a five-minute reten-
tion interval in the home cage, ADR animals spent a signifi-
cantly lower proportion of time exploring the novel object
compared to Controls (P = 0.01) and ADR+ PLX5622 (P =
0.007) groups (Fig. 1b). Conversely, ADR+ PLX5622
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treated animals did not differ from Control animals. We
did not include a Control + PLX5622 group as past reports
from our laboratory and others show that short- or long-
term treatment with PLX5622 did not affect cognitive func-
tion in intact, control animals [4, 24, 43]. After NOR test-
ing, animals were habituated and tested in the OiP arena.
During the OiP test phase, a significant group difference
was found between the treatment cohorts for the discrimin-
ation index (F(2, 27) = 6.36, P = 0.006). Control and ADR +
PLX5622 cohorts showed comparable preference for the
objects placed at novel locations (Fig. 1c) whereas ADR-
treated animals receiving control diet showed significantly
less preference to novel locations compared to ADR +
PLX5622 animals (P = 0.006). For each of the above open
arena tasks, the overall tendency of ADR-treated co-
horts was to explore less during the NOR and OIP
phases (Additional file 1: Figure S2). Our past data
evaluating CYP-induced cognitive impairments showed
similar reductions in the total exploration times compared
to control animals [5]. Though, reduced time exploring
the objects was less likely to impact discrimination be-
tween the novel and familiar object. Additionally, Wil-
coxon matched-pairs signed rank tests comparing familiar
and novel exploration times revealed significant effects for
the Control (P = 0.002) and ADR + PLX5622 (P = 0.002)
for both NOR and OIP tests whereas differences for the
ADR group were not statistically significant.
Our past data showed impaired contextual fear mem-
ory after chronic chemotherapy [5, 22]. Thus, to ascer-
tain if CSF1R inhibition exert beneficial effects on the
fear memory, animals were administered fear condition-
ing task. Each phase of the FC task (training, cue and
context tests) were administered over 3 days. Repeated
measures ANOVA showed a significant overall group ×
phase interaction effect for the percentage of time spent
freezing during the FC task (Fig. 1d; F(4, 108) = 103.4, P =
0.0001). Repeated measures two-way ANOVA for each
phase revealed significant differences between ADR and
ADR + PLX5622 groups in the post-training (P = 0.001)
and context (P = 0.01) phases. Groups did not differ sig-
nificantly in freezing behavior across baseline, pre-cue,
and post-cue phases, indicating a selective deficit in the
hippocampal-dependent contextual memory phase of
the task. The extent of freezing observed during the con-
text phase is similar to that reported by our groups and
others in the field [5, 22, 44, 50]. During the context test
phase, post hoc tests confirmed that ADR animals spent
significantly decreased percentages of time freezing com-
pared with Control (P = 0.006) and ADR + PLX5622
(P = 0.01) groups, whereas Control and ADR + PLX5622
groups did not differ. Moreover, all groups showed sig-
nificant increases in freezing behavior after the tone-
shock pairings (post-training phase) indicating that ADR
treatment did not impair sensory function. These data
corroborate our past findings that exposure to chemo-
therapy significantly impairs learning and memory func-
tion [5, 22].
CSF1R inhibition reduced microglial activation in the
ADR-treated brains
We have demonstrated previously that cancer therapy
(cranial irradiation or chemotherapy)-induced microglial
activation contributes to cognitive impairments [3–5, 22].
To determine the effectiveness of dietary treatment with
CSF1R inhibitor, the number of IBA-1+ and CD68+ acti-
vated microglia was quantified (Figs. 2 and 3). The chronic
ADR treatment did not affect the numbers of IBA-1+
microglial cells 6 week post-treatment, but ADR-treated
mice receiving the PLX5622 diet showed a significant de-
pletion in the number of IBA-1+ microglial cells (Fig. 2a-c,
F(2, 15) = 266.3, P = 0.0001). 3D algorithm-based volumetric
quantification of IBA-1+ microglial cells showed that
CSF1R inhibition led to > 95% reduction in IBA-1 immu-
noreactivity in ADR-treated brains as compared to Con-
trol and ADR groups (Fig. 2d; P = 0.0001). Chronic
chemotherapy significantly increased the CD68 immuno-
reactivity of activated microglia that was mitigated by
PLX5622 treatment (Fig. 3a-c, CD68, P = 0.001 versus
Control group). The overall group difference for CD68
immunoreactivity was also significant (F(2, 15) = 61.96; P =
0.0001) and PLX5622 treatment significantly ablated
CD68 immunoreactivity in the ADR-exposed brain as
compared to Control and ADR groups (Fig. 3d, P =
0.0001). These data indicate that chemotherapy-induced
microglial activation was, at least in part, associated with
cognitive impairments.
CSF1R inhibitor reduced pro-inflammatory signatures in
the ADR-treated brain
The foregoing data indicated that chronic chemotherapy-
induced neuroinflammation and cognitive dysfunction
could be reversed by CSF1R inhibition. Pro-inflammatory
cytokine signaling trigger cascades of events that may lead
to persistent microglial activation and disruption of brain
function [33]. To corroborate these findings, we carried
out multiplex ELISA for cytokines and, gene expression
analyses from freshly dissected hippocampal tissues
(Fig. 4). Chronic ADR treatment significantly elevated
levels of IL-1β, IL-3, IL-5, IL-12, GM-CSF and RANTES
(Regulated on Activation, Normal T Cell Expressed and
Secreted, CCL5, Fig. 4a). Administration of PLX5622 to
the ADR-treated animals led to a significant decline in the
levels of IL1α, IL-3, IL-4, IL-5 and GM-CSF while MIP-1a
and CCL5 were elevated by PLX5622 treatment. Gene ex-
pression analyses showed elevated pro-inflammatory sig-
natures in the ADR-treated brain, including IL-6, IL-4,
IL11ra1, Tnfsf13b and Cfi (Fig. 4b). Again, treatment with
PLX5622 reduced inflammatory gene expression levels in
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the ADR-treated brains. Taken together, CSF1R inhibition
reduced neuroinflammation in the ADR-treated brains
that is linked with improvements in the cognitive
function.
iMG-EV treatment reversed ADR-induced cognitive
dysfunction
Our data emphasize the role of microglia in disrupting
normal brain function after the exposure to cytotoxic
cancer therapy. Our past studies have shown beneficial
effects of reducing CNS inflammation by various strat-
egies including CSF1R inhibition [4], reduction of astro-
gliosis [2] and, stem cell-derived EV treatment [17]. In
the next set of experiments, 1 week after last ADR treat-
ment, animals were treated with iMG-derived EV once
weekly for 4 weeks via retro orbital vein injection
(Fig. 5A; 1.36 × 107 EVs per injection). Control mice re-
ceiving EV treatment were not included given it is not
clinically relevant and the control brain does not show
measurable neuroinflammation pathology. One week
after the last EV injection, animals were habituated and
administered the NOR spontaneous exploration task.
The overall group differences between each treatment
cohort were significant (F(2, 21) = 8.914, P = 0.002) for the
NOR test phase (Fig. 5B). The ADR-treated mice spent
significantly less time exploring the novel object com-
pared to Control mice receiving vehicle (P = 0.002).
iMG-EV treatment significantly improved the perform-
ance of ADR treated mice (P = 0.01 vs ADR group) as in-
dicated by comparable exploration to the novel objects
as in the Control group. Moreover, Wilcoxon matched-
pairs signed rank test comparing familiar and novel ex-
ploration times revealed significant effect for the Control
(P = 0.02) and ADR + iMG-EV (P = 0.01) groups whereas
exploration times for the ADR group were statistically
indifferent (Additional file 1: Figure S3).
Fig. 2 Dietary treatment with CSF1R inhibitor depletes IBA-1+
microglia from the ADR-treated hippocampus. Quantification for the
IBA-1 immunoreactivity using immunofluorescence staining, laser
scanning confocal microscopy and 3D volumetric-based analysis
demonstrates that treatment with PLX5622 for 6 weeks eliminates
IBA-1+ microglia from the ADR-treated (ADR + PLX5622) brains
(green, IBA-1; blue, DAPI nuclear counter stain). a-c Representative
confocal micrographs for IBA-1 immunostaining from the
hippocampal dentate gyrus showing dentate hilus (DH), granule cell
layer (GCL) and CA1 sub-regions from the control and ADR groups
receiving control diet and, ADR-treated mice receiving PLX5622 diet
(insert, high resolution image of IBA-1+ cell). d 3D algorithm-based
quantification (Autoquant and Imaris) of IBA-1+ microglia show > 96%
depletion in the ADR + PLX5622 group. Data are presented as
mean ± SEM (N = 4–6 mice per group). P values are derived from
ANOVA and Bonferroni’s post hoc test. *, + P < 0.0001 compared
with Control and ADR groups respectively. Scale bars, 200 μm,
a-c 5 μm, insert
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Our past and current data show that chemotherapy
impairs contextual fear conditioning memory (Fig. 1d)
[5, 22]. Next, we conducted fear extinction (FE) memory
testing to decipher if chemo-treated mice could acquire
and subsequently extinguish conditioned fear responses
(fear memory consolidation). During the conditioning
phase of FE testing, all groups of mice (Control, ADR
and ADR + iMG-EV) exhibited comparable associative
learning as demonstrated by similar times spent freezing
during the tone-shock conditioning phase (Fig. 5C; T1-
T3; 44 to 49% on T3). During the subsequent extinction
training days, mice were presented with 20 tones per day
(5 s intervals) in the same context as the conditioning
phase with no foot shock. The ADR-treated animals
continued to show increased freezing as compared to
the Control and ADR + iMG-EV groups (Fig. 5C; Extinc-
tion Training Day 1 and 2, P = 0.01). These data indi-
cated that iMG-EV injections to the ADR-exposed
animals mitigated impairments in the ability to dissoci-
ate the learned response (freezing) to a prior aversive
event (tone-shock pairing). Twenty-four hours after
completion of extinction training, the mice were admin-
istered extinction testing (3 tones, 120 s intervals) in the
same testing environment as used for extinction training.
The extinction test revealed significant group effects
(Fig. 5c1; F(2, 21) = 10.97, P = 0.001). ADR mice demon-
strated an inability to abolish fear memories during this
retrieval testing and again exhibited increased freezing
that was ameliorated by iMG-EV injections (Fig. 5 c1;
P = 0.01 vs ADR group). Moreover, Wilcoxon matched-
pairs signed rank test show that Control and ADR +
iMG-EV groups spent significantly less time freezing on
the test day versus the first training day (Additional file
1: Figure S4, P = 0.002, training vs test day). This
hippocampus-dependent FE testing paradigm provides a
relative invasive measure of elevated anxiety and impair-
ments in fear memory consolidation, and demonstrated
that chemotherapy induced impairments similar to a
post-traumatic stress disorder that can be abolished by
repeated injections with iMG-derived EV.
Fig. 3 CSF1R inhibitor treatment reduces CD68+ activated microglia from the ADR-treated hippocampus. Immunofluorescence staining, confocal
microscopy and 3D algorithm-based volumetric quantification show that PLX5622 treatment for 6 weeks significantly reduced CD68+ activated
microglia (red, CD68; blue, DAPI nuclear counterstain) in the ADR-treated brains. a-c Representative confocal micrographs for CD68
immunostaining from the hippocampal dentate gyrus showing dentate hilus (DH) and granule cell layer (GCL) from the Control and ADR groups
receiving control diet and ADR-treated mice receiving PLX5622 diet (insert, magnified image of CD68+ cell). d 3D algorithm-based quantification
(Autoquant and Imaris) of CD68+ activated microglia show > 60% reduction in the ADR + PLX5622 group. Data are presented as mean ± SEM
(N = 4–6 mice per group). P values were derived from ANOVA and Bonferroni’s post hoc test. *, + P < 0.0001 compared with Control and ADR
groups respectively. Scale bars, 70 μm, a-c 5 μm, insert
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iMG-EV treatment attenuates microglial activation
iMG-EV treatment-mediated improvements in cognitive
function indicate the importance of modulating inflam-
matory system in the chemo-treated brains. Microglia
play a critical role in sustaining learning and memory
behaviors [45, 53]. Immunohistochemistry and volumet-
ric quantification were carried out to determine the
status of microglia in the ADR treated brain following
iMG-EV treatment (Fig. 6). As observed previously (Fig. 2),
chronic chemotherapy did not affect the immunoreactivity
of IBA-1+ microglial cells (Fig. 6a, b). Close evaluation of
IBA-1+ cells in the ADR-treated brain showed typical
amoeboid, round microglial morphology with stout pro-
cesses (Fig. 6a, white arrows) indicating activation status
Fig. 4 Cytokine profile and gene expression analyses of ADR and ADR-treated mice brains receiving PLX5622. a Determination of hippocampal
cytokine profile (ELISA) showed significant alterations in the IL-1a, IL-1β, IL-3, IL-4, IL-5, MIP-1a, GM-CSF and Rantes (CCL5) levels (pg per ml of
hippocampal suspension) in the ADR and ADR + PLX5622 treated brains compared to Controls. b Gene expression analysis of microglial and
inflammatory markers from the mice hippocampus show upregulation of pro-inflammatory signatures in the ADR-treated brains. Data are
presented as mean ± SEM (N = 3 to 5 mice per group). *, P < 0.05; **, P < 0.01 compared with ADR group. +, P < 0.05; ++, P < 0.003 compared with
control group
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Fig. 5 (See legend on next page.)
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after ADR treatment. This observation was confirmed by
CD68 staining to visualize activated microglia (Fig. 6c).
Chronic ADR treatment significantly increased CD68
immunoreactivity compared to controls (P = 0.0001).
Conversely, iMG-EV treatment significantly reduced
activated microglia in the ADR-treated brain (Fig. 6d,
P = 0.0001). These data demonstrate the neurotoxic
role of microglia in the chemo-treated brains and,
provide evidence that iMG-EV treatment can attenu-
ate microglial activation and remediate chemobrain.
Discussion
Cancer survivors experience emotional, behavioral and
cognitive decrements long-term post-treatment in the ab-
sence of cancer, seriously impacting quality of life [7, 42].
With significant increases in the number of cancer survi-
vors, chemobrain represents a critical survivorship issue
with notable absence of clinical recourse. Therefore, strat-
egies to restore cognition and normal brain function fol-
lowing the successful completion of cancer therapies are
clearly needed. The current pre-clinical literature and our
(See figure on previous page.)
Fig. 5 Extracellular vesicles (EV) isolated from human induced pluripotent stem cell (iPSC)-derived microglia (iMG) prevent the development of
Adriamycin-induced cognitive dysfunction. a Schematic of the experimental design: adult wild type (C57BL/6 J) male mice received chronic
Adriamycin (ADR) treatment (2 mg/kg, i.p.) once weekly for 4 weeks. One week after the last ADR injection animal received intravenous (retro
orbital vein) injections of iMG-EV (1.36 × 107 EVs per injection in 50 μL volume, once weekly for 4 weeks). One week after iMG-EV injections, mice
were administered novel object recognition (NOR) and fear extinction memory (FE) tasks. After completion of cognitive testing, brains were
harvested for immunohistochemical analyses. b Chronic ADR treatment caused a significantly reduced discrimination index (DI) on the NOR task
(**, P < 0.002 compared to Controls). ADR-treated mice receiving iMG-EV injections (ADR + iMG-EV) show a significant improvement in
performance on the NOR task (*, P < 0.01 compared to the ADR group). c Neither treatment with ADR nor iMG-EV impaired the acquisition of
conditioned fear as indicated by elevated freezing following a series of 3 tone-shock pairings (0.6 mA, T1-T3). 24-h after the conditioning phase,
fear extinction training was administered every 24-h (20 tones) for 2 days. All mice showed a gradual decrease in freezing behavior (Day 1–2),
however, ADR-treated mice spent a significantly higher percent time in freezing compared to controls (*, P’s < 0.01). c1 24 h after extinction
training, Control and ADR + iMG-EV mice showed abolished fear memory compared to ADR-treated mice receiving vehicle (*, P < 0.01; **, P <
0.002 compared to ADR group). Data are presented as mean ± SEM (N = 8 mice per group). P values were derived from ANOVA and Bonferroni’s
post hoc test
Fig. 6 Extracellular vesicles (EV) isolated from human induced pluripotent stem cell (iPSC)-derived microglia (iMG) reduce neuroinflammation. a, b
Immunofluorescence staining, confocal microscopy and 3D algorithm-based quantification for the IBA-1+ cells (IBA-1, green; blue, DAPI nuclear
counter stain) show that neither chronic ADR treatment, nor retro-orbital vein injections of iMG-EV altered the IBA-1+ microglial population in the
hippocampus (DH, dentate hilus; GCL, granule cell layer). ADR treated mice (a, middle panel) show amoeboid morphology (white arrows)
characteristic of microglial activation. c, d Chronic treatment with ADR elevated CD68+ activated microglia in the hippocampus (DH, dentate
hilus; GCL, granule cell layer). iMG-EV injections significantly reduced the CD68 immunoreactivity indicating attenuation of inflammation. Data are
presented as mean ± SEM (N = 6 mice per group). *, P < 0.001 compared with ADR group. P values were derived from ANOVA and Bonferroni’s
post hoc test. Scale bars: a 20 μm and c 40 μm
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past data have shown that neurocognitive impairments cor-
relate with elevated pro-inflammatory cytokines and neuro-
inflammation [5, 22, 40]. The activation of microglia is also
linked with several neurodegenerative conditions, including
radiation and chemo-therapy-related brain injury. Thus, we
targeted common neuropathological sequelae – CNS in-
flammation – to ameliorate chemotherapy-related cognitive
impairments.
Using a relevant rodent model of cranial radiation-
induced brain injury, we have shown previously that ad-
ministration of a highly specific, brain penetrant CSF1R
inhibitor (PLX5622) eliminated microglia (> 96%) in the
irradiated brain within 3 days post initiation of dietary
treatment and, importantly, ameliorated radiation-
induced behavioral decrements that were evaluated 4–6
weeks after irradiation [4]. In the current study, as a
proof-of-the-concept, we employed a similar strategy
using a rodent model of chemobrain to show the effect-
iveness of CSF1R inhibition. Animals were treated with
chronic ADR (doxorubicin) treatment, a commonly used
breast cancer chemotherapy, and 72 h later initiated
dietary administration of PLX5622 for 4–6 weeks. As
previously reported [22], chronic ADR treatment caused
significant impairments in the recognition of novelty,
shown by inability of animals to recognize new objects
or locations on each of the spontaneous exploration,
open field tasks. Deficits were also found on the contextual
fear-conditioning task, suggesting that neurocognitive defi-
cits were associated with hippocampal-dependent learning
and memory function. ADR-treated animals receiving
PLX5622 showed significant improvements in performance
on all behavioral tasks suggesting cognitive benefits of
microglia depletion. We did not include a group of control
mice receiving PLX5622 treatment as the data from our la-
boratory and others have shown that CSF1R inhibition itself
did not alter cognitive function [4, 24, 43]. In depth analyses
using immunohistochemistry and 3D volumetric-based
quantification, cytokine ELISA, and RNA sequencing con-
clusively determined the impact of microglia depletion in
the chemo-treated hippocampus. The chronic ADR treat-
ment did not alter the number of IBA-1 positive microglia,
and treatment with PLX5622 eliminated > 95% of microglia
in the ADR-treated brains. This is in line with our previous
findings showing microglia depletion in the irradiated brain
[4]. Similarly, Green and colleagues have shown the effect-
iveness of CSF1R inhibition in neurodegenerative disease
models suggesting that CSF1R inhibition was equally effect-
ive in other brain injury scenarios [43, 47]. Quantification
of CD68 immunoreactivity, an indicator of activated micro-
glia, in the ADR-treated brain showed about 1.5-fold eleva-
tion in inflammation that was reduced significantly by the
CSF1R blockade. Treatment with Adriamycin has been
shown to elevate plasma TNFɑ that may perturb the blood
brain barrier integrity and exacerbate inflammatory cascade
in the brain leading to neuroinflammation [48]. Our gene
expression data showed elevation in a pro-inflammatory,
supra-family member TNF ligand, Tnfsf13b in the ADR-
treated brain. Although, we have not tested this directly,
ADR-induced infiltrated macrophage/ monocytes in the
CNS may also express CD68 in response to the pro-
inflammatory environment. Suppression of microglial acti-
vation may yield a plethora of effects on neuronal function,
as a large body of literature suggests that activated micro-
glia can exert neurotoxic effects via such routes as produc-
tion of oxidative or nitrosative stress or TNFα and cytokine
secretions that may damage neurons and glia [28]. A single
injection of ADR has been shown to induce acute elevation
(3 to 72 h) in apoptotic response genes, mitochondrial
dysfunction and elevated TNFɑ in the brain [48]. Taken to-
gether, these studies indicate ADR-mediated early neuro-
pathological alterations that lead to persistent inflammation
and disruption in cognitive function at later post-treatment
intervals. Microglia have been shown to regulate synaptic
integrity by actively remodeling synaptic and perisynaptic
environment via complement signaling that could be dis-
rupted when the brain exhibits persistent microglial activa-
tion [23]. Our past data have shown the detrimental effects
of chronic chemotherapy on neuron structure and spine
density that was linked with microglial activation [5].
Although, we did not analyze neuron morphologic parame-
ters in the current study, the ability of CSF1R inhibition to
attenuate neuroinflammation provides one plausible ex-
planation for the beneficial neurocognitive outcomes in the
ADR-treated brain.
Neurodegenerative or pathological events, including
irradiation and chemotherapy, have been shown to in-
duce cytokine-mediated immune response in the CNS
[19, 26, 30]. Our multiplex ELISA data showed ele-
vated levels of pro-inflammatory cytokines in the
ADR-treated hippocampus including IL-1β, IL-3, IL-5,
IL-12 and GM-CSF. CNS is capable of producing low
levels of cytokines that modulates the function of
neurons, astrocytes and microglia [33]. IL-1β, IL-3,
IL-5 and GM-CSF are early indicators of the cranial
radiation-induced inflammatory response [30] and studies
have reported key roles for these cytokines in promoting
neuroinflammation and deterioration of hippocampal-
dependent learning and memory formation [29]. IL-1β
overexpression has been shown to impair hippocampal-
dependent contextual fear memory [29] which is in line
with our data showing ADR-induced elevation of IL-1β and
impairments in the contextual as well as extinction of fear
memories. IL-1β signaling activates microglia and increases
pro-inflammatory cytokine responses that could lead to
neuroinflammation and cognitive dysfunction [29]. IL-12 is
a mediator of inflammatory neurodegenerative conditions
including multiple sclerosis [19]. IL-12 is produced by
microglia and astrocytes in the brain and triggers the
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detrimental degenerative consequences in the CNS via
STAT4-dependent induction of IFN-y production [19].
Our data show elevation in the IL-12 and IFN-y in the
ADR-exposed hippocampus that links microglial activation
and cognitive dysfunction. Both IL-1β and IL-12 levels were
reduced following PLX5622 treatment, albeit not statisti-
cally significant in comparison with the ADR group. GM-
CSF is essential for the expansion of pro-inflammatory
immune responses. Elevated or dysregulated GM-CSF is
also associated with neuroinflammation and brain injury in
humans [8]. CSF1R inhibition significantly reduced GM-
CSF levels in the brains of chemo-treated animals
indicating attenuation of neuroinflammation. Inter-
estingly, the brains of ADR-treated animals receiving
PLX5622 show a notable elevation in levels of RANTES ex-
pression. RANTES, also known as CCL5, plays neurotrophic
and neuroprotective roles in the brain. For example, CCL5
induces proliferation of oligodendrocyte precursors [34],
regulates differentiation of astrocytes [14] and, exerts neuro-
protective effects against glutamate-, β-amyloid- or HIV
protein gp120-induced neurotoxicity [18, 20, 31]. The ob-
served increase in protein and transcript levels of the neuro-
protective CCL5 in the brains of PLX5622-treated animals
supports our data demonstrating reduced cognitive dysfunc-
tion and anti-inflammatory effects of CSF1R inhibition.
These findings clearly indicate quenching of chemokine
signaling by CSF1R inhibition in the chemo-treated brain
that likely dampens the recruitment and/or activation of
microglia.
One of the striking findings of this study is the preven-
tion of chemotherapy-induced cognitive impairments by
human iPSC microglia-derived EV. Human iPSC-derived
microglia (iMG) are highly similar to cultured human
adult and fetal microglia in terms of molecular signa-
tures and show functional characteristics of migration,
secretion of cytokines and phagocytosis in vitro and
in vivo [1, 41]. The basis of this approach stems from
our past studies showing the beneficial neurocognitive
effects of human neural stem cells (hNSCs) or hNSC-
derived EV in reversing cranial radiation-induced brain
injury [3, 17]. EV are secreted from cells in nearly all
known tissues, and can play a role in maintaining nor-
mal homeostasis or in many disease pathologies, includ-
ing cancer [49]. EV are now recognized as important
circulating biomarkers, as well as therapeutic candidates
[12]. EV have been shown to display low immunogen-
icity, can cross the blood-brain barrier, and fuse and
deliver cargo to specific cell types in the brain [12]. In
our study, repeated intravenous injections (once weekly
for 4 weeks) of iMG-derived EV prevented the development
of chemotherapy-related cognitive impairments as reflected
by increased time-spent exploring the novel object. More-
over, chemotherapy-induced elevation in the microglial acti-
vation was attenuated by iMG-EV treatment. Activated
microglia and elevated pro-inflammatory cytokines plays
disruptive role in fear memory consolidation [45, 53]. Our
data show elevated signatures of pro-inflammatory cyto-
kines, including IL-1β and TNF ligand suprafamily member,
Tnfsf13b, after chronic ADR exposure that may explain ele-
vated freezing levels (impaired memory consolidation) dur-
ing the fear extinction trials. ADR-treated mice receiving
iMG-EV injections show improvements in fear memory
consolidation reflected by reduced time spent freezing dur-
ing fear extinction training and testing phases. Interestingly,
during the cue-phase of fear conditioning (Fig. 1d) we ob-
serve comparable elevated freezing in the Control and ADR
groups showing intact amygdala function. This freezing be-
havior was abolished when ADR-treated mice administered
extinction training in the same context (Fig. 5C, extinction
training day 1 and 2). This data signifies the rigor of our
testing platform and demonstrate that hippocampal-
amygdala circuit is also disrupted following chemotherapy,
and that additional therapeutic strategy of re-switching the
chemo-injured CNS microenvironment to less inflammatory
and thereby promoting recovery from chemobrain. Indeed,
reports suggest beneficial and anti-inflammatory effects of
microglia- or immune cell-derived EV on the CNS function.
Repeated intra-nasal delivery of macrophage-derived EV
loaded with catalase decreased microglial activation in the
6-hydroxydopamine (6-OHDA)-induced acute inflamma-
tion model of Parkinson’s disease [27]. An in vitro study
showed neuroprotective effects of EV derived from mono-
meric α-synuclein treated microglia on the MPP-injured
cultured neurons [37]. Intracranial delivery of EV isolated
from microglia and mesenchymal stem cell co-cultures pro-
moted oligodendrocyte precursor cell differentiation and
remyelination whereas inflammatory microglia-derived EV
had opposite effects [39]. Our past findings have shown that
cranial injections of hNSC-derived EV protected neuronal
dendritic structure, spine density and, significantly reduced
microglial activation in the irradiated brain [17]. The forego-
ing reports show equivalent beneficial effects of intra-cranial
and systemic delivery of EV. Injected EV have been shown
to fuse or co-localize with various CNS subtypes, and deliver
bioactive cargo to produce functional effects [10, 17, 39, 52].
Further work is warranted to investigate the molecular cargo
(miRNAs, proteins etc.) of iMG-EV to delineate the benefi-
cial anti-inflammatory effects of EV in the chemobrain
model.
Taken together, our findings implicate CNS inflamma-
tion, particularly microglial activation, as one of the
major causal factor in perpetuation of chemobrain. Ex-
tensive studies by Green and co-workers have shown no
adverse physiological or behavioral effects of short- or
long-term depletion of microglia via CSF1R inhibition in
acute brain injury, aging and Alzheimer’s disease mouse
models [25, 43, 46]. Depletion of microglia prior to
neuronal insult aggravated the injury, whereas microglia
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elimination following the neuronal injury promoted re-
covery [43]. On the other hand, sustained microglia
elimination in the young (1.5 month old) 5xFAD mouse
brain prevented plaque formation over extended period
of time (7 month of age) whereas re-population of
microglia upon CSF1R inhibitor withdrawal lead to ro-
bust plaque formation [46]. Similarly, our past study
using a clinically relevant irradiation paradigm did not
show adverse physiological effects of PLX5622 treatment
on the control animals [4]. Moreover, no adverse impact
of PLX5622 treatment on neural stem and oligo-
progenitor cell proliferation and differentiation was ob-
served [36, 38]. Therefore, we posit that PLX5622
treatment-mediated reduction in microglia and neuroin-
flammation contributed significantly to restoring cogni-
tive function. The gist of these studies also indicate that
depletion of microglia from the injured or neurodegen-
erative environment with subsequent re-population
upon CSF1R inhibitor withdrawal may serve as a useful
strategy. A range of CSF1R inhibitors are currently
under clinical trials [21] for the treatment of cancers in-
cluding metastatic breast cancer (NCT01596751), ovar-
ian cancer (NCT01525602), colorectal and pancreatic
cancer (NCT02777710), solid tumors (NCT02452424)
and, for rheumatoid arthritis (NCT01329991). Thus,
CSF1R inhibition strategies may serve dual potentials in
killing cancer and protecting the normal tissue function.
Whether CSF1R inhibition strategies (short- or long-
term) to eliminate microglia or attenuation of CNS in-
flammatory microenvironment via EV treatment after
clinically relevant adjuvant chemotherapy paradigms re-
main to be determined. Our study showing beneficial
neurocognitive and anti-inflammatory effects of attenu-
ating microglial activation support our hypothesis that
neuroinflammation is one of the major drivers in
chemotherapy-induced cognitive dysfunction. With che-
mobrain incidence rates as high as 75% in breast cancer
survivors, minimally invasive strategies targeting neuro-
inflammation can provide clinical recourse for this un-
met medical need.
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Supplemental Figure S1. Effects of Adriamycin, PLX5622 and iMG-EV treatment on animal 
body weight. Treatment with Adriamycin, PLX5622 or iMG-EV did not change the body weight 
of animals significantly. Data are presented as mean ± SEM (N = 8 to 10 mice per group) for the 
percentage change from the initial body weight. 
  
Supplemental Figure 2. Effects of ADR and PLX5622 treatment on total time spent 
exploring objects during the NOR and OIP tasks. ADR-treated animals spent significantly less 
time exploring novel objects or places. A, Time spent exploring the novel object and, B, Time 
spent exploring novel placements of objects during the test phases of novel object recognition 
(NOR) and object in place (OIP) tasks, respectively. Control and ADR + PLX5622 treated mice 
spent significantly more time exploring novel versus familiar object (NOR) or location (OIP) 
whereas ADR treated mice spent comparable time exploring novel and familiar object or places. 
Data are presented as mean ± SEM (N = 10 mice per group). P values were derived from 
Wilcoxon matched-pairs signed rank test. *, P < 0.002.   
 
 
 
 
 
 
 
 
  
 
Supplemental Figure 3. Effects of ADR and iMG-EV treatment on total time spent exploring 
objects during the NOR and OIP tasks. Chronic ADR treatment reduced the time spent 
exploring novel objects. Time spent exploring the novel object during the test phase of the novel 
object recognition task shows that Control and ADR + iMG-EV treated mice spent significantly 
more time exploring novel versus familiar object whereas ADR treated mice spent comparable 
time exploring novel and familiar objects. Data are presented as mean ± SEM (N = 8 mice per 
group). P values were derived from Wilcoxon matched-pairs signed rank test. *, P < 0.01.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 4. Effects of ADR and iMG-EV treatment on percent time spent 
freezing during the extinction trial and extinction test phases. Disrupted fear memory 
consolidation following chronic ADR treatment. Control and ADR + iMG-EV treated mice spent 
significantly less time freezing during extinction test phase versus the first day of extinction 
training trails. In contrast ADR-treated mice receiving vehicle spent more time freezing during 
both extinction training and extinction test phases. Data are presented as mean ± SEM (N = 8 
mice per group). **, P < 0.002 compared to extinction training day 1, Wilcoxon matched-pairs 
signed rank test. +, P < 0.01 compared to Control; ++ P < 0.002 compared to ADR + iMG-EV group 
derived from Bonferroni’s post hoc test.   
Materials and Methods 
Animals and treatments 
All animal procedures described in this study are approved by the University of California 
Institutional Animal Care and Use Committee and, according to the federal (NIH) guidelines.  
Animals were housed in a pathogen-free facility certified by AAALAC.  Six-month old male wild 
type mice (C57BL/6J, Jackson) were maintained in standard housing conditions (20°C ± 1°C; 
70% ± 10% humidity; 12 h:12 h light and dark cycle) and had free access to standard rodent chow 
and water.  Adriamycin (ADR, doxorubicin hydrochloride, Sigma) was dissolved in saline and 
delivered via intraperitoneal (i.p.) injection once weekly for four weeks (2 mg/kg) as shown in the 
study design (Fig. 1A). For the CSF1R inhibition study, mice were divided into three experimental 
groups (N = 10-12 mice per group): saline treated control mice receiving control chow (Control), 
ADR-treated mice receiving control chow (ADR) and, ADR-treated mice receiving PLX5622 chow 
(ADR + PLX5622). 72 hours after the last ADR injection mice were provided the control or 
PLX5622 chow.  CSF1R inhibitor, PLX5622 chow, was provided by Plexxikon (Berkeley, CA) and 
formulated in AIN-76A standard chow by Research Diets (New Brunswick, NJ) at a dose of 1200 
PPM. Control mice received AIN-76A chow without PLX5622.  All mice were maintained on their 
respective PLX5622 or control diet throughout the duration of the study.  
 Extracellular vesicles (EV) were isolated from human iPSC-derived microglia. Human 
microglia (iMG) were differentiated by a simplified method from human iPSC-derived 
mesoderdermal, hematopoietic stem cells as described (1,2).  RNA sequencing, phagocytosis, 
and transplantation studies validated the functional microglial characteristics of these cells. 
Briefly, large batches of conditioned medium were collected by Cellular Dynamics, Inc. Research 
and Development Laboratory (Madison, WI) during the maturation phase (days 28 to 35) of the 
differentiated iMG culture and refrigerated conditioned media was shipped to UCI for the isolation 
of EV. EV isolation was carried out using the ultracentrifugation protocol as described in detail 
(Thery).  Briefly, large cell debris was removed by sequential centrifugations using increasing 
speeds (300 × g, 5 min; 2,000 × g, 10 min; 10,000 × g, 30 min; all at 4 °C).  At each step the pellet 
was discarded and the supernatant carried forward. After filtration from 0.2 µm filter,  EV were 
pelleted by ultracentrifugation using 100,000 × g (70 min, 4 °C). The pellet was then washed in 
sterile PBS to remove contaminating proteins and re-pelleted by centrifugation at 100,000 × g for 
an additional 70 min.  EV quantity and size were determined using a Zetaview particle analyzer 
(ZetaView PMX 110; Meerbusch, Germany). The iMG conditioned media yielded a total of 7.07 × 
1011 EV per ml with the mean diameter of 65 nm. The purified EV were stored in sterile phosphate 
buffered saline (PBS, 100 mM, pH 7.4, Gibco) at 4°C. Animals were divided into three groups (N 
= 8 mice per group): Controls receiving PBS (Controls), ADR-treated receiving PBS (ADR) and 
ADR receiving iMG-EV injection via retro-orbital sinus route of administration once weekly for four 
weeks (1.36 × 107 EV per 50 µL per injection; ADR + iMG-EV). We did not observe significant 
effects of any of these treatments on animal body weights (Suppl. Fig. 1).  
 
Cognitive testing 
To determine the effect of CSF1R inhibition on cognitive function after chronic 
chemotherapy, mice were administered behavioral testing four weeks after the initiation of 
PLX5622 treatment. Testing spanned over three weeks including the spontaneous exploration 
tasks Novel Object Recognition (NOR) and Object in Place (OiP), followed by the contextual and 
cued fear conditioning (FC) task.  The NOR task evaluates episodic recognition memory through 
measuring the preference of mice to investigate novel environmental changes, whereas the OiP 
task evaluates associative recognition memory (3,4).  Both tasks were conducted as described 
previously (5). Briefly, NOR and OiP testing occurred in a dimly lit (48 lux) test arena (30 × 30 × 
30 cm) containing fresh corn cob bedding and was video recorded from the ceiling.  All bedding 
was replaced and the arena was thoroughly cleaned with 10% ethanol between trials.  For the 
NOR task mice were initially habituated to the empty arena for three days (10 min/day). The 
following testing day, two plastic objects (differing in color, shape and size) were magnetically 
affixed 16 cm apart in the arena and the mouse was allowed five minutes to explore the objects. 
The mouse was returned to the home cage for five minutes while one familiar object was 
substituted for a novel object (both objects were cleansed with 10% ethanol). The mouse was 
then returned to the arena for five minutes of further exploration. Three days after completion of 
the NOR task, OiP task was administered, including, two days (10 min/day) of habituation. On the 
third day, mice explored an arena with four unique objects for five minutes before briefly returning 
to their home cage (5 min). All objects were cleansed with 10% ethanol and the location of two 
objects was swapped before the mouse was returned for five more minutes of exploration. Videos 
of both tasks were scored to obtain times spent interacting (nose within 2 cm) with familiar versus 
novel (or relocated) objects by observers blind to the experimental groups to avoid bias. The 
discrimination index was then calculated for each mouse from these values: [(Novel/Total 
exploration time) – (Familiar/Total exploration time)] × 100. After completion of spontaneous 
exploration tasks, the FC task was administered in three sequential phases over three days 
including a training phase (5 tone and shock pairings, a context test for 5 min and a cue for 5 min 
test as described previously (6,7).    
For the iMG-EV treatment study, mice were administered behavior testing one week after 
the last EV injection (5 weeks after the last ADR treatment). These tests include NOR and fear 
extinction (FE) memory testing. NOR testing was carried out as described above. To determine if 
chronic chemotherapy or EV treatment affects amygdala-hippocampal circuit-dependent fear 
conditioning learning and fear memory consolidation, we performed a series of FE assays 
modified to be reliant on hippocampal function (8,9) . Testing occurred in a behavioral conditioning 
chamber (17.5  × 17.5  × 18 cm, Coulbourn Instruments) with a steel slat floors (3.2 mm diameter 
slats, 8 mm spacing).  Throughout the conditioning, memory consolidation (extinction training) 
and extinction testing phases, the bottom acrylic collection plate was scented with a spray of 10% 
acetic acid in water. For the initial fear conditioning phase (day 1), mice were allowed to habituate 
to the chamber for two minutes. Three pairings of an auditory conditioned stimulus (16 kHz tone, 
80 dB, lasting 120 sec; CS) co-terminating with a foot shock unconditioned stimulus (0.6 mA, 1 
sec; US) were presented at two minute intervals. On the following two days of extinction training, 
mice were initially habituated to the same context for two minutes before being presented with 20 
non-US reinforced CS tones (16 kHz, 80 dB, lasting 120 sec, at 5 sec intervals). On a final day of 
fear testing mice were presented with only three non-US reinforced CS tones (16 kHz, 80 dB, 
lasting 120 sec) at two minute intervals in the same context. Freezing behavior was recorded with 
a camera mounted above the chamber and scored by an automated measurement program 
(FreezeFrame, Coulbourn Instruments).  FreezeFrame algorithms calculate a motion index for 
each frame of the video, with higher values representing greater motion. An investigator blinded 
to the experimental groups set the motion index threshold representing immobility for each animal 
individually, based on identifying a trough separating low values during immobility and higher 
values associated with motion. Motion index thresholds were set between 14-15 for all animals. 
Freezing behavior was defined as continuous bouts of one second or more of immobility. The 
percentage of time each mouse spent freezing was then calculated for each phase of the fear 
response testing. 
 
Immunohistochemistry, confocal microscopy and volumetric quantification 
After completion of behavioral testing, mice were deeply anesthetized using isoflurane 
and euthanized via intercardiac perfusion using saline with heparin (10 U/ml, Sigma) followed by 
4% paraformaldehyde PBS (ACROS Organics, NJ).  Brains were cryoprotected using a sucrose 
gradient (10-30%) and sectioned coronally into 30 μm thick sections using a cryostat (Leica 
Microsystems, Germany). For each endpoint 3-4 representative coronal brain sections from each 
of 4-6 animals per experimental group were selected at approximately 15 section intervals to 
encompass the rostro-caudal axis from the middle of hippocampus (2.1 to 2.9 mm from bregma) 
and stored in PBS. Free floating sections were first rinsed in PBS, blocked for 30 min in 4% (w/v) 
bovine serum albumin (BSA) and 0.1% Triton X-100 (TTX).  For the immunofluorescence analysis 
of microglia, the following primary and secondary antibodies and dilutions were used: rabbit anti-
IBA-1 (1:500, Wako), rat anti-mouse CD68 (1:500, AbD Serotec), donkey anti-rabbit or anti-
mouse conjugated with Alexa Fluor 488 or 594 (Life Technologies/Invitrogen).  Tissues were DAPI 
nuclear counterstained (15 µm in PBS) and mounted with gold slow fade/antifade mounting 
medium (Life Technologies).  IBA-1+ cells were visualized under fluorescence as green, CD68+ 
cells as red and, nucleus as blue. 
Immunofluorescent sections were imaged using Nikon Eclipse Ti C2 microscope to obtain 
20 to 30 z stacks (1024 × 1024 pixels, 0.5 to 1 μm each) using 20 and 40× PlanApo oil-immersion 
lens (Nikon). For quantification of IBA-1+ and CD68+ cells, 3D deconvolution and reconstruction 
was carried out using the AutoQuantX3 algorithm (MediaCybernetics). Deconvolution combined 
with 3D reconstruction yields higher spatial resolution images for the immunofluorescent cell 
bodies and stellae ((10,11)). Quantification was facilitated using Imaris filament and spot tool 
(v9.2, Bit Plane Inc., Switzerland) that detect immunostained puncta within 3D deconvoluted 
image stacks based on a predefined diameter and red/green channel intensity threshold. IBA-1 
and CD68 data are expressed as mean immunoreactivity (percentage) relative to the vehicle-
treated controls. 
 
Cytokine and gene expression analyses 
Freshly dissected hippocampi from each brain (N = 3-5 per group) were washed and 
homogenized with 200 μl of PBS containing complete protease inhibitor cocktail (Sigma) using a 
motorized pellet pestle (Sigma) at 4°C.  Supernatants were collected after serial washing in PBS 
(500 × g and 15,000 × g, 5 minutes each at 4°C) and shipped to Quansys Biosciences (Logan, 
UT) for the multiplex analysis of cytokines using Q-Plex 14 cytokine array kit. Positive readouts 
were reported and plotted as the mean ± SEM. For the gene expression analysis, total mRNA 
was extracted from the freshly dissected hippocampi using the RNA Plus Universal Mini Kit 
(Qiagen), and were hybridized and multiplexed with NanoString probes according to the 
manufacturer's instructions. Microglial function and pro-inflammatory genes were analyzed using 
the NanoString nCounterTM mouse immunology panel (NanoString Technologies).  Counts for 
target genes were normalized to housekeeping genes (EEF1G, G6PDX, HPRT, POLR1B, 
POLR2A, PPIA, RPL19, SDHA and TBP) to account for variability in RNA content. Background 
signal was calculated as a mean value of the negative hybridization control probes. Gene 
expression values were presented as percentage of vehicle-treated control group. 
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